Protein S100-A6 Antibodies

Protein S100-A6 (S100A6)

May be the calcium sensor and modulator, contributing to cellular calcium signaling. May function by interacting with other proteins, such as TPR-containing proteins, and play a role in several physiological processes such as the reorganization of the actin cytoskeleton and in cell motility.

Binds 2 calcium ions. Calcium binding is cooperative.

Gene Information

Human
Gene Name:	S100A6
Uniprot:	P06703
Entrez:	6277

Family

Belongs to:
S-100 family

Alternative Names

2A9; CABP; CACY; CACY5B10; calcyclin; Growth factor-inducible protein 2A9; MLN 4; PRA; PRAS100 calcium binding protein A6 (calcyclin); Prolactin receptor-associated protein; protein S100-A6; S100 calcium binding protein A6; S100 calcium-binding protein A6 (calcyclin); S100 calcium-binding protein A6; S100A6

Molecular Weight

Mass (kDA):
10.18 kDA

Genomic Context

Human
Location:	1q21.3
Sequence:	1; NC_000001.11 (153534599..153536049, complement)

Subcellular Localizations

Nucleus envelope. Cytoplasm. Cell membrane; Peripheral membrane protein; Cytoplasmic side.

Diseases

• Neoplasms
• Malignant Neoplasms
• Carcinoma
• Malignant Paraganglionic Neoplasm
• Neoplasm Metastasis
• Cell Transformation, Neoplastic
• Skin Neoplasms
• Melanoma
• Adenocarcinoma
• Carcinoma, Ehrlich Tumor
• Cell Invasion
• Pancreatic Neoplasm
• Malignant Neoplasm Of Breast

• Tumor Progression
• Malignant Neoplasm Of Pancreas
• Malignant Squamous Cell Neoplasm
• Inflammation
• Stomach Neoplasms
• Mammary Neoplasms
• Liver Neoplasms

Interacting Proteins

• FKBP4
• KPNA2
• MDM2
• PEX5
• S100B

Pathways

• Cell Proliferation
• Cell Cycle
• Localization
• Methylation
• Pathogenesis
• Cell Growth
• Secretion
• Cell Differentiation
• Cell Migration
• Exocytosis
• Regeneration
• Cell Adhesion
• Cell Motility

• Transport
• Senescence
• Cell Death
• Dna Methylation
• Immune Response
• Translation
• Hair Cycle

PTMs

• Phosphorylation
• Methylation
• Ubiquitination
• Cleavage
• Acetylation

• Dephosphorylation
• Biotinylation
• Nitrosylation
• Glutathionylation
• Cysteinylation

Research Areas

• Apoptosis
• Cancer
• Cell Biology
• Cell Cycle and Replication
• Cellular Markers

• Chromatin Research

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/S100A6

Best Uses of the Anti-S100 Alpha 6 (S100A6) Marker in Pancreatic Cancer and Molecular Diagnostics

If you're curious about the benefits of using the Anti-S100 Alpha 6 (S100A6) Marker in molecular diagnostics, you've come to the right place. Read on for the best uses of this marker in pancreatic cancer, Molecular Diagnostics, and other areas. There's no need to wait for a cancer diagnosis; start using this marker today!

Anti-S100 Alpha 6 (S100A6) Marker

The S100A6 protein is a member of the family of low-molecular-weight calcium-binding proteins. It has over 20 isoforms and is associated with a wide range of cellular functions, including signaling, membrane excitability, and muscle contraction. The S100A6 gene is responsible for modulating ERK1/2 signaling and beta-catenin signaling.

This gene is ubiquitously expressed in mammalian cells, including endothelial cells and fibroblasts. It also inhibits antiproliferative STAT1 signaling. The role of S100A6 in vascular repair has been elucidated by gene expression time-series analysis and bioinformatic pathway modeling. This discovery led to the identification of key components that regulate the expression of S100A6.

The Anti-S100 Alpha 6 (S100 A6) Marker in Boster Bio is a monoclonal antibody that reacts with S100A6 protein in both human and mouse cells. It has been validated on multiple platforms and has high affinity and specificity. Moreover, Boster rewards early reviewers with product credits and recognizes scientists worldwide. This demonstrates that high-quality antibodies can make a difference in your research.

This antibody recognizes the expression of S100A6 in colorectal cancer tissue. Unlike the S100P and S100A4 proteins, the S100A6 marker is highly specific for detecting adenoma. Similarly, S100A9 and S100A11 mRNA in advanced colorectal cancer are not associated with colorectal neoplasia in men.

S100A9 immunoreactivity has been identified in both normal and cancerous bone tissues. Its inhibition inhibits the proliferation of cancer cells in U2OS and MG63 cells. These results are backed up by microarray data. S100A9 may prove to be a promising therapeutic target for OS. So, the S100A9 immunoreactive antibody is available in Boster Bio.

Studies have shown that S100A9 mRNA levels are higher in OS tumors compared with normal bone tissues. The researchers concluded that S100A9 expression is linked to OS carcinogenesis and that a good quantification of S100A9 mRNA might serve as a screening test in patients with OS. However, they did not report the results of this study.

Molecular Diagnostics

Molecular Diagnostics with the S100A6, also known as S100A6, is a low-molecular-weight calcium-binding protein. It belongs to the S100 family and functions as a homodimer. It binds to two Caper monomers through non-covalent interactions. S100A6 has an EF-hand structure, a pair of a helices joined by a short loop region.

Molecular Diagnostics with the S100A6, or S100A6-positive, blood samples, can be used in cancer diagnosis. The detection kit is available from Amersham Biosciences, a laboratory based in Bucks, UK. The Invitrogen company offers See blue plus 2 pre-stain standards for detecting the S100A6-positive cells. The test uses a tailored algorithm that uses many diagnostic statements to reach a binary conclusion.

This marker was developed by studying the transcriptome data of TRAM1 and S100A6. Using the TRAM1 and S100A6 markers, the RNA species of each gene was checked to ensure specific amplification. Both primers target bold transcripts, resulting in a calculated lg(fc) value for protein coding transcripts. The RNA species used is categorized as protein-coding, processed, or retained intron.

Moreover, the S100A6 marker was recently identified as a potential risk marker for cholangiocarcinomas. It was also found to correlate with tumour grade in astrocytic tumours. This protein is also a differentially expressed gene in pancreatic adenocarcinomas. This means that a single marker may provide a definitive diagnosis for patients suffering from cholangiocarcinoma.

Recent studies suggest that S100A6 expression is increased in tumors with amplification of the DNA sequence of the gene. The loss of S100A6 expression is associated with hypermethylation of CpG sites. Furthermore, this marker could be useful in prostate cancer diagnosis. This marker may eventually replace many other tumor markers for a variety of diseases. So, Molecular Diagnostics with the S100A6 marker is a promising way to diagnose cancer.

The S100A6 marker is present in the brain and has two ligands, Sgt1 and CacyBP/SIP. It is expressed in many brain structures, including neurons and oligodendrocytes. It also interacts with tau and Hsp90 proteins. In the future, S100A6 may be used in diagnostic tests for neurodegenerative diseases.

Pancreatic Cancer

While not yet a clinically validated marker, S100A6 mRNA has shown promise as a diagnostic tool and a therapeutic target in pancreatic cancer. This marker is highly expressed in pancreatic cancer tissues and may have clinical implications. For instance, it has been shown to be up-regulated in PANC-1 and hTERT-HPNE pancreatic cancer cells, although it is down-regulated in MIA PaCa-2 pancreatic cancer cells.

S100A6 mutations alter gene expression and have been linked to decreased survival in pancreatic cancer. The cBioPortal tool was used to analyze genetic changes in S100A2/4/6/10/14/16. It identified 55 samples of pancreatic cancer patients with S100A2 mutations. The mutation rates were 9, 12, 11, 14, 8, and 13%, respectively. The resulting data were plotted on a Kaplan-Meier plot. A log-rank test identified an association between the mutation rate and shorter OS and PFS.

A recent study suggests that the S100A family of proteins may be a potential therapeutic target for pancreatic cancer. The findings support the notion that the expression of S100As in cancer may predict the function and progression of related genes. However, further studies are needed to determine whether the S100A6 gene expression is elevated in the tumour tissue. In the meantime, S100A6 expression may be a helpful diagnostic tool in pancreatic cancer.

The S100A6 gene is up-regulated in pancreatic cancer and has been linked to several other neurological diseases. It has also been linked to prostate adenocarcinoma and Pilomatrixoma. Additionally, S100A6 is associated with the synthesis of prostaglandins, a critical factor in pancreatic cancer.

In pancreatic cancer, it is important to find the best way to use this gene to improve patient care. The best way to do this is to screen pancreatic cancer tissues using S100A2/4/6/10/14/16 in the Oncomine database. Moreover, this gene's promoter methylation levels were significantly lower in PDAC tissue. In addition, S100A6 expression is associated with a poor prognosis. However, effective detection and treatment strategies are still needed.

A recent study has shown that S100A6 can distinguish cancer-related and normal pancreatic tissues. In addition to cancer-related pathways, it also has a strong relationship with TIME. In vitro functional assays have revealed that S100A6 helped PC cells proliferate and migrate. In the future, it may be used to detect cancer-related tumors and detect other diseases.